Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

A new study has shed light on the health risks faced by people who stop using weight-loss medications Ozempic or Wegovy.

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Fidelity International Capital Appreciation Fund is a diversified international equity strategy that seeks capital growth by ...

As demand for Wegovy quickly outpaced supply, other industry competitors began to jump into the obesity market. This trend ...

GLP-1 agonist Wegovy (semaglutide ... production capacity for their obesity drugs as demand has outstripped supply, hoping to generate clear air between them and a large pack of companies trying ...

This shows the huge demand and gap in supply. Manchanda believes that in the coming two ... the reduction will be significant ...

(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for ...

The company last week noted that the last remaining dose in short supply, the lowest dose of Wegovy, is now listed as ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...